MedTrace Logo

Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT

NCT06408753 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-05-10

No results posted yet for this study

Summary

This is a prospective study to investigate the biomarkers in predicting treatment outcome and toxicity in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors with or without stereotactic body radiotherapy (SBRT).

Conditions

  • Hepatocellular Carcinoma Non-resectable
  • Stereotactic Body Radiotherapy

Interventions

PROCEDURE

sterotatic body radiotherapy

checkpoint inhibitors with or without sterotatic body radiotherapy

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2023-11-30
Completion
2024-03-27

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06408753 on ClinicalTrials.gov